367 related articles for article (PubMed ID: 19505187)
1. Clinical development of novel proteasome inhibitors for cancer treatment.
Yang H; Zonder JA; Dou QP
Expert Opin Investig Drugs; 2009 Jul; 18(7):957-71. PubMed ID: 19505187
[TBL] [Abstract][Full Text] [Related]
2. An analysis of the safety profile of proteasome inhibitors for treating various cancers.
Wang H; Guan F; Chen D; Dou QP; Yang H
Expert Opin Drug Saf; 2014 Aug; 13(8):1043-54. PubMed ID: 25005844
[TBL] [Abstract][Full Text] [Related]
3. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
[TBL] [Abstract][Full Text] [Related]
4. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
Yang H; Landis-Piwowar KR; Chen D; Milacic V; Dou QP
Curr Protein Pept Sci; 2008 Jun; 9(3):227-39. PubMed ID: 18537678
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
6. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
Wang H; Yang Q; Dou QP; Yang H
Curr Protein Pept Sci; 2018 Feb; 19(4):358-367. PubMed ID: 28079010
[TBL] [Abstract][Full Text] [Related]
8. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
Golden EB; Lam PY; Kardosh A; Gaffney KJ; Cadenas E; Louie SG; Petasis NA; Chen TC; Schönthal AH
Blood; 2009 Jun; 113(23):5927-37. PubMed ID: 19190249
[TBL] [Abstract][Full Text] [Related]
9. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
Kuhn DJ; Orlowski RZ; Bjorklund CC
Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.
Soave CL; Guerin T; Liu J; Dou QP
Cancer Metastasis Rev; 2017 Dec; 36(4):717-736. PubMed ID: 29047025
[TBL] [Abstract][Full Text] [Related]
11. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
12. Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Orlowski RZ; Zeger EL
Expert Opin Investig Drugs; 2006 Feb; 15(2):117-30. PubMed ID: 16433592
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment.
Zhang L; Wu M; Su R; Zhang D; Yang G
Recent Pat Anticancer Drug Discov; 2022; 17(3):268-283. PubMed ID: 34856915
[TBL] [Abstract][Full Text] [Related]
16. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
17. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
Frezza M; Schmitt S; Dou QP
Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
[TBL] [Abstract][Full Text] [Related]
18. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
19. Positioning of proteasome inhibitors in therapy of solid malignancies.
Roeten MSF; Cloos J; Jansen G
Cancer Chemother Pharmacol; 2018 Feb; 81(2):227-243. PubMed ID: 29184971
[TBL] [Abstract][Full Text] [Related]
20. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
